Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.99 K % +36.4%
Debt-to-equity 9.05 % -30.7%
Return On Equity -13.5 % +34.3%
Return On Assets -12.4 % +31.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.7 M shares +23.5%
Common Stock, Shares, Outstanding 51.8 M shares +24%
Entity Public Float 280 M USD +36.5%
Common Stock, Value, Issued 51 K USD +21.4%
Weighted Average Number of Shares Outstanding, Basic 49 M shares +17.4%
Weighted Average Number of Shares Outstanding, Diluted 49 M shares +17.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 53.1 M USD -10.1%
General and Administrative Expense 27 M USD +13.6%
Operating Income (Loss) -72.9 M USD +1.32%
Nonoperating Income (Expense) 17.3 M USD +157%
Net Income (Loss) Attributable to Parent -55.6 M USD +17.2%
Earnings Per Share, Basic -1.2 USD/shares +25.9%
Earnings Per Share, Diluted -1.2 USD/shares +25.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 213 M USD +601%
Accounts Receivable, after Allowance for Credit Loss, Current 519 K USD -30.8%
Assets, Current 659 M USD +105%
Property, Plant and Equipment, Net 6.52 M USD -9.52%
Operating Lease, Right-of-Use Asset 20.5 M USD -6.69%
Other Assets, Noncurrent 2.52 M USD +56.7%
Assets 689 M USD +95.2%
Accounts Payable, Current 2.25 M USD +9.9%
Employee-related Liabilities, Current 1.33 M USD -3.36%
Accrued Liabilities, Current 5.81 M USD -24.9%
Contract with Customer, Liability, Current 972 K USD -80.3%
Liabilities, Current 10.6 M USD -34.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 22.6 M USD -6.5%
Liabilities 33.2 M USD -20.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -524 K USD +29.1%
Retained Earnings (Accumulated Deficit) -184 M USD -43.5%
Stockholders' Equity Attributable to Parent 656 M USD +111%
Liabilities and Equity 689 M USD +95.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.8 M USD -6.66%
Net Cash Provided by (Used in) Financing Activities 322 M USD +20291%
Net Cash Provided by (Used in) Investing Activities -114 M USD -1201%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 51.8 M shares +23.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 45 M USD +45.2%
Deferred Tax Assets, Gross 52.6 M USD +35.2%
Operating Lease, Liability 24.2 M USD -5.31%
Depreciation 532 K USD +17.4%
Payments to Acquire Property, Plant, and Equipment 197 K USD -30.9%
Lessee, Operating Lease, Liability, to be Paid 34.1 M USD -8.89%
Property, Plant and Equipment, Gross 9.96 M USD +15.6%
Operating Lease, Liability, Current 1.57 M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.61 M USD +3.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.51 M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.92 M USD -16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72 M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 18.7 M USD +15.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 2.39 M USD +87.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.83 M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.65 M USD -3.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%